Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

129.30 +0.50 (+0.39%)
Streaming Delayed Price Updated: 10:26 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
3 Long-Term Winners from Charles Schwab’s Top Picks
Explore the growth and resilience of long-term stocks Microsoft, Merck and Veralto in the latest Charles Schwab stocks portfolio update. 
Via InvestorPlace
For those who appreciate value investing, NYSE:MRK is a compelling option with its solid fundamentals.
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024. 
Via InvestorPlace
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
What the Options Market Tells Us About Merck & Co
Via Benzinga
Exploring The Competitive Space: Merck &amp; Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
2 Monster Stocks to Buy Without Any Hesitation
Investors can sleep easy at night with these stocks in their portfolios. 
Via The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks
Via Benzinga
Topics Economy
Exposures Economy
Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock
Via Benzinga
3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report
Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth. 
Via InvestorPlace
Drivers And Stock Pickers
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient. 
Via Talk Markets
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
Via Benzinga
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... 
Via Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024." 
Via Benzinga
Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued. 
Via Chartmill
7 Mutual Funds That Will Outperform in Any Market
While we’d all love to think we’re market geniuses, we could use the active management of outperforming mutual funds. 
Via InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.